Clinical Trial Update: Switching From Oral Dopamine Agonists to Rotigotine [Phase 4]

View source ↗

Summary

A Phase 4 trial update reports the completion of a study on switching from oral dopamine agonists to Rotigotine for restless legs syndrome, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• Rotigotine (rotigotine)

Snippet

Sponsor: John Winkelman, MD, PhD | Conditions: Restless Legs Syndrome, Ekbom Syndrome | Phase 4 | Status: COMPLETED | Results posted: 2016-10-13